Is Colgate-Palmolive Company (CL) Undervalued? Valuation & Fair Price
At $86.06, 4 of the 4 frameworks would pass on Colgate-Palmolive Company today — Warren Buffett, Benjamin Graham, Peter Lynch, and Phil Town (Rule #1) rate it Avoid. Each model calculates its own fair value and margin of safety; create a free account to see the exact buy price behind every verdict.
Colgate-Palmolive Company
CLConsumer Defensive · Household & Personal Products · NYSE
$86.06
P/E 36.3×
CEO
Noel R. Wallace
Sector
Consumer Defensive
Industry
Household & Personal Products
Website
www.colgatepalmolive.comOperating globally, Colgate-Palmolive Company and its affiliated entities are engaged in the production and distribution of a diverse range of consumer goods. Its operations are structured into two primary divisions: Oral, Personal and Home Care, and Pet Nutrition. The Oral, Personal and Home Care division encompasses a broad array of offerings, spanning oral hygiene (e.g., toothpastes, toothbrushes, mouthwashes), personal care (e.g., bar and liquid soaps, shower gels, shampoos, conditioners, deodorants, antiperspirants, skin health items), and home care solutions (e.g., dishwashing detergents, fabric conditioners, household cleaners). These products are distributed through various channels, including traditional and online retailers, wholesalers, and distributors, under well-known brand names such as Colgate, Darlie, elmex, hello, meridol, Sorriso, Tom's of Maine, Irish Spring, Palmolive, Protex, Sanex, Softsoap, Lady Speed Stick, Speed Stick, EltaMD, Filorga, PCA SKIN, Ajax, Axion, Fabuloso, Murphy, Suavitel, Soupline, and Cuddly. Furthermore, this segment supplies specialized pharmaceutical products to dentists and other professionals in oral healthcare. Conversely, the Pet Nutrition segment focuses on providing specialized pet food. This includes everyday nutritional options marketed under the Hill's Science Diet brand, as well as therapeutic diets designed to assist in managing various health conditions in dogs and cats, sold under the Hill's Prescription Diet brand. Distribution for these pet nutrition items occurs via pet supply stores, veterinary clinics, and online retail platforms. Established in 1806, Colgate-Palmolive Company maintains its corporate headquarters in New York, New York.
Investor scorecard
How the four investors rate Colgate-Palmolive Company
4 of 4 frameworks urge caution
Investor model analysis
Details lockedAt $86.06, 4 of 4 frameworks say Avoid
Intrinsic Value (DCF)
Warren Buffett's valuation model · select an investor above to switch
Intrinsic Value
Locked — upgrade to viewBuy Below
Locked — upgrade to viewStrong Buy
Locked — upgrade to viewMargin of Safety
Locked — upgrade to viewUnlock buy targets with a free account
Get startedCreate a free account to see buy targets, full checklists & risk analysis Get started
Insider & congress activity
Are insiders buying CL?
Over recent SEC Form 4 filings, CL insiders bought $0 and sold $32.0M of stock across 6 open-market trades. Insiders sell for many reasons, but they buy for one.
| Insider | Action | Shares | Value | Date |
|---|---|---|---|---|
| Tsourapas PanagiotisCOO, CD, EMEA, APac, Skin | Sell | 10,000 | $920K | Aug 24, 2026 |
| CAHILL JOHN Tdirector | Sell | 4,170 | $389K | Aug 6, 2026 |
| Wallace Noel R.Chairman, President & CEO | Sell | 161,021 | $14.9M | Aug 5, 2026 |
| Wallace Noel R.Chairman, President & CEO | Sell | 161,021 | $14.8M | Aug 4, 2026 |
| Malcolm GregoryEVP and Controller | Sell | 2,300 | $203K | May 15, 2026 |
Members of Congress have also reported 50 trades in CL. See the full insider & congress timeline.
Source: SEC Form 4 filings. Open-market buys & sells only. Not investment advice.
See the interactive insider chart & every tradeScenario analysis
Bear, base & bull
Three growth assumptions, three fair values — and where today's price lands
What's working
Key strengths
Identified by Buffett framework analysis
Company financials
5-Year Financials
Income statement highlights — annual, USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $20.4B | $20.1B | $19.5B | $18.0B | $17.4B |
| Rev. Growth | +1.4% | +3.3% | +8.3% | +3.1% | — |
| Net Income | $2.1B | $2.9B | $2.3B | $1.8B | $2.2B |
| Net Margin | 10.5% | 14.4% | 11.8% | 9.9% | 12.4% |
| EPS (Diluted) | $2.64 | $3.53 | $2.78 | $2.13 | $2.56 |
| Free Cash Flow | Locked — upgrade to view | Locked — upgrade to view | Locked — upgrade to view | Locked — upgrade to view | Locked — upgrade to view |
Full analysis included
See the complete picture for CL
Exact buy targets, margin of safety, detailed investor checklists, and risk breakdown — all frameworks, all numbers.
Free: 3 analyses/month · Pay per stock: $4.99 · Pro: $19.99/mo
More Consumer Defensive stocks
Educational Use Only · Not Financial Advice
Analysis, scores, valuations, and buy zones are derived from publicly documented investor frameworks (Buffett, Lynch, Benjamin Graham, Phil Town) for learning purposes only. They are not recommendations from licensed financial advisors. Past performance does not guarantee future results. Prices may be delayed up to 15 minutes. Always conduct your own research before making any investment decisions.